Lupus ‐like cutaneous reaction following pembrolizumab: an immune‐related adverse event associated with anti‐PD‐1 therapy

In this report, we describe a patient who developed a lupus‐like cutaneous reaction in the setting of pembrolizumab therapy for metastatic melanoma, adding to the spectrum of reactions which may be observed in association with PD‐1 inhibitor therapy.

Source: Journal of Cutaneous Pathology - October 13, 2017 Category: Pathology Authors: Kimberly Shao, Suzanne McGettigan, Rosalie Elenitsas, Emily Y. Chu Tags: CASE REPORT Source Type: research